1610P - Survey of outpatient cancer chemotherapy: occurrence of side effects and reasons for discontinuation or delay

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Complications/Toxicities of Treatment
Presenter Hideyuki Kushihara
Authors H. Kushihara1, K. Kawada2, T. Kushihara3, N. Hamajima4, M. Amano4, K. Ooji4, K. Honda2, F. Nomura2, Y. Ikeda1, K. Mori1
  • 1Pharmacy, Japanese Red Cross Nagoya Daiichi Hospital, 453-8511 - Nagoya/JP
  • 2Medical Oncology, Japanese Red Cross Nagoya Daiichi Hospital, 4538511 - Nagoya/JP
  • 3Pharmacy, Japanese Red Cross Nagoya First Hospital, 453-8511 - Nagoya/JP
  • 4Nursing, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya/JP



In cancer chemotherapy, patients have various side effects. In general, if patients' quality of life is negatively affected (e.g., toxicity of grade 3 or higher), the treatment will be discontinued. On the other hand, if symptoms are mild or moderate (e.g., toxicity of grade 2 or lower), the treatment will be continued with supportive therapy. Patients with mild or moderate side effects must tolerate such adverse effects for a prolonged period. Therefore, to continue chemotherapy safety, it is very important to understand the extent of symptoms and to provide suitable supportive care as required. We conducted a survey of outpatient cancer chemotherapy.


We retrospectively investigated the characteristics of side effects and the reasons for discontinuation or delay of chemotherapy between July 2009 and March 2011 at Nagoya Daiichi Red Cross Hospital in Japan.


Data on 924 patients (8221 cases) were analyzed. The following data are presented in the order of grade 2 and grade 3 or higher. Nonhematologic toxicities were constipation (32.0, 0.7%), fatigue (21.3, 2.7%), anorexia (17.0, 0.6%), neuropathy (15.3, 1.4%), nausea (14.4, 0.6%), pain (13.7, 1.0%), vomiting (7.5, 0.6%), diarrhea (6.3, 0.2%), dysgeusia (6.0, − %), oral mucositis (4.1, 0.1%), and nail changes (3.6, 0.1%). Hematologic toxicities were neutropenia (16.3, 19.1%), thrombocytopenia (4.1, 2.1%), and anemia (26.1, 7.0%). Nonhematologic toxicities Grade 2 or lower had a high average incidence of 44.6%. Chemotherapy was discontinued in 1341 patients (16.3%). The reasons for discontinuation or delay were laboratory abnormalities (35.4%), chief complaints of patients (34.0%), and others (30.1%).


In patients with grade 3 or higher toxicity, appropriate care was provided, including dose reduction or discontinuation of treatment. In patients with grade 2 or lower toxicity, treatment tended to be continued. Our results showed that a large proportion of patients tolerate mild or moderate side effects that do not lead to discontinuation or delay of treatment. It is necessary to evaluate the extent of symptoms and to provide supportive care from an early stage.


All authors have declared no conflicts of interest.